Blog

Urine albumin-to-creatinine ratio (ACR or UACR) is the gold standard test for early diabetic kidney disease. ACR compares the amount of albumin (a protein normally retained by healthy kidneys) to creatinine (excretion relatively constant) in a single spot urine sample. The ratio (mg of albumin per gram of creatinine) provides a reliable measure of urinary albumin excretion accounting for urine concentration. ACR detects kidney damage years before changes in serum creatinine or eGFR. ADA recommends annual ACR screening for all adults with diabetes (type 2 from diagnosis; type 1 starting 5 years after diagnosis). KDIGO standard categories (A1, A2, A3): A1 normal/mild (ACR under 30 mg/g), A2 moderate microalbuminuria (30-300), A3 severe macroalbuminuria (over 300), nephrotic-range over 3,000. Results may vary day-to-day; abnormal results should be confirmed with repeat testing 1-2 times over 3-6 months. ACR combined with eGFR provides comprehensive CKD staging — KDIGO Heat Map classifies adults into 12 risk cells. Both measures provide independent information: eGFR shows filtering capacity, ACR shows kidney damage. Elevated ACR indicates need for ACE inhibitor or ARB (reduces ACR 30-50%), SGLT2 inhibitor (kidney protection from CREDENCE, DAPA-CKD trials), aggressive glucose and blood pressure control, finerenone (Kerendia) for T2D + CKD, and lifestyle modifications.

ACR Categories and CKD Staging

KDIGO Combined eGFR and ACR Heat Map

Why ACR Matters for Diabetes

• Detects kidney damage years before creatinine/eGFR changes.
• Strong predictor of progression to kidney failure.
• Strong predictor of cardiovascular events (independent of kidney function).
• Often reversible if caught early — intervention can return ACR to normal.
• Identifies adults who benefit most from ACE/ARB therapy.
• Identifies adults who benefit from SGLT2 inhibitors.
• End-stage kidney disease (dialysis) is preventable through early action.
• About 40% of adults on dialysis have diabetes — early screening saves kidneys.

How ACR Is Tested

• Random spot urine sample (most common).
• First morning urine often preferred (more concentrated).
• Lab measures albumin and creatinine concentrations separately.
• Calculates ratio: albumin (mg) / creatinine (g).
• Results typically within 24-48 hours.
• Point-of-care tests at some clinics for same-day results.
• 24-hour urine collection — alternative; less convenient; rarely needed.
• Modest cost; covered by most insurance.

Causes of False-Positive Results

• Recent strenuous exercise (within 24 hours).
• Fever or acute illness.
• Urinary tract infection.
• Menstruation (avoid testing during).
• Heart failure decompensation.
• Severe uncontrolled hypertension.
• Recent high-protein meal.
• Pregnancy (preeclampsia screening uses separate criteria).
• Hematuria (visible or microscopic blood).
• Repeat testing 1-3 months after to confirm persistent elevation.

Treatment for Elevated ACR

• ACE inhibitor or ARB: first-line; reduces ACR 30-50%.
• SGLT2 inhibitor: empagliflozin, dapagliflozin, canagliflozin — kidney protection.
• Finerenone (Kerendia): for T2D + CKD with albuminuria.
• GLP-1 agonists: modest kidney benefit; semaglutide, dulaglutide.
• Tight glucose control: A1C under 7%.
• Aggressive blood pressure: under 130/80.
• Sodium reduction: under 2.3 g daily.
• Modest protein reduction: 0.8 g/kg if not malnourished.
• Weight loss: 5-10% if overweight.
• Smoking cessation: significantly reduces progression.
• Avoid NSAIDs: ibuprofen, naproxen damage kidneys.
• Treat coexisting conditions: hypertension, dyslipidemia.

Frequency Recommendations

• Type 2 diabetes: annually from diagnosis.
• Type 1 diabetes: annually starting 5 years after diagnosis.
• Hypertension + diabetes: annually regardless.
• Established CKD: every 6 months.
• Elevated ACR (over 30): repeat in 2-3 months; then every 3-6 months.
• Pregnant women with diabetes: each trimester.
• Children with type 1 diabetes: age 11 or 5 years after diagnosis.
• Adults on hemodialysis: not routinely useful.

The Bottom Line

Urine albumin-to-creatinine ratio (ACR or UACR) is the gold standard test for early diabetic kidney disease. ACR compares albumin (a protein normally retained by healthy kidneys; damaged kidneys allow it to leak into urine) to creatinine (excretion relatively constant) in a single spot urine sample, accounting for urine concentration differences. ACR detects kidney damage years before changes in serum creatinine or eGFR. ADA recommends annual ACR screening for all adults with diabetes (type 2 from diagnosis; type 1 starting 5 years after diagnosis). KDIGO standard categories: A1 normal/mild (ACR under 30 mg/g), A2 moderate microalbuminuria (30-300), A3 severe macroalbuminuria (over 300). Results may vary day-to-day; abnormal results should be confirmed with repeat testing 1-2 times over 3-6 months. Causes of false-positive: recent strenuous exercise, fever/illness, UTI, menstruation, severe hypertension, recent high-protein meal — avoid testing during these. ACR combined with eGFR provides comprehensive CKD staging through KDIGO Heat Map (12 risk cells). About 40% of adults on dialysis have diabetes — early ACR screening saves kidneys. Treatment for elevated ACR: ACE inhibitor or ARB (first-line, reduces ACR 30-50%), SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin — kidney protection from CREDENCE, DAPA-CKD, EMPA-KIDNEY trials), finerenone (Kerendia) for T2D + CKD, GLP-1 agonists (modest kidney benefit), tight glucose control (A1C under 7%), aggressive blood pressure (under 130/80), sodium reduction (under 2.3 g daily), modest protein moderation (0.8 g/kg if not malnourished), weight loss 5-10% if overweight, smoking cessation, avoid NSAIDs (ibuprofen, naproxen damage kidneys). Often reversible if caught early — combined approach may return ACR to normal. End-stage kidney disease requiring dialysis is preventable through annual screening and early action. For adults with type 2 diabetes, ACR is among the most important annual tests — insist on it as part of routine diabetes care alongside eGFR. See our broader nephropathy guide for context.

hsCRP (high-sensitivity C-reactive protein) measures systemic inflammation in the body. CRP is produced by the liver in response to inflammation; “high-sensitivity” testing detects low levels associated with chronic disease. hsCRP is independently associated with cardiovascular disease risk — elevated values predict heart attacks and strokes even when cholesterol levels are normal. Categories: under 1 mg/L low risk, 1-3 average, over 3 high, over 10 acute inflammation. Diabetes typically elevates hsCRP due to chronic low-grade inflammation — baseline 2-5 mg/L is common, higher than non-diabetic peers. Mechanisms: hyperglycemia stimulates inflammatory cytokines, adipose tissue (especially visceral fat) produces TNF-α and IL-6, insulin resistance is associated with chronic inflammation, often coexisting hypertension and obesity compound inflammation. Effective hsCRP reduction interventions: Mediterranean diet (strong evidence), weight loss (5-10% reduces significantly), regular exercise (both aerobic and resistance), glucose control (A1C reduction), smoking cessation (major reduction), reduce alcohol, statins (direct anti-inflammatory effect beyond cholesterol lowering), aspirin (modest), address dental/periodontal disease, treat sleep apnea, sleep adequacy, stress management, omega-3 fatty acids (modest), avoid processed foods/refined carbs/trans fats. The JUPITER trial demonstrated that statin therapy in adults with elevated hsCRP but normal LDL reduced cardiovascular events by 44%. Not all adults need routine hsCRP testing; most useful for refining risk assessment in intermediate cardiovascular risk.

hsCRP Risk Categories

What Elevates hsCRP

• Chronic conditions: diabetes, obesity, hypertension, cardiovascular disease.
• Smoking — major contributor.
• Periodontal/gum disease.
• Autoimmune disease (lupus, rheumatoid arthritis).
• Infections — acute and chronic.
• Recent surgery or trauma — transient elevation.
• High alcohol intake.
• Sedentary lifestyle.
• Poor diet (processed foods, refined carbs, trans fats).
• Sleep deprivation.
• Chronic stress.
• Sleep apnea.
• Cancer (some types).
• Inflammatory bowel disease.
• Pregnancy (modest elevation normal).

Why hsCRP Matters Beyond Cholesterol

• JUPITER trial (Ridker 2008): statin therapy in adults with normal LDL but elevated hsCRP reduced cardiovascular events by 44%.
• hsCRP predicts cardiovascular events independently of LDL.
• Some adults have normal cholesterol but elevated cardiovascular risk — hsCRP identifies them.
• ACC/AHA risk calculator includes hsCRP as risk enhancer.
• Reclassifies adults from “low” to “moderate” risk in some cases.
• Useful for adults with intermediate risk to decide on statin therapy.
• Less useful for adults already at high risk (statin indicated regardless).
• Less useful for adults at very low risk (no intervention needed).

Lifestyle Interventions to Reduce hsCRP

• Mediterranean diet: strong evidence; multiple studies show 15-40% reduction.
• Weight loss: 5-10% body weight typically reduces hsCRP 25-50%.
• Regular exercise: 150 min/week reduces hsCRP modestly.
• Resistance training: additional benefit beyond aerobic.
• Smoking cessation: major reduction within months.
• Glucose control: A1C reduction correlates with hsCRP reduction.
• Sleep adequacy: 7-9 hours nightly.
• Stress management: meditation, yoga, therapy.
• Reduce processed foods: refined carbs, trans fats raise inflammation.
• Increase omega-3: fatty fish 2x weekly.
• Limit alcohol: moderate use only.
• Dental care: treat periodontal disease.
• Treat sleep apnea: if present.

Medications That Reduce hsCRP

• Statins: direct anti-inflammatory effect beyond cholesterol lowering.
• Aspirin: modest anti-inflammatory effect.
• Colchicine: anti-inflammatory; under study for cardiovascular prevention.
• SGLT2 inhibitors: modest hsCRP reduction.
• GLP-1 agonists: modest hsCRP reduction.
• Metformin: modest hsCRP reduction.
• Anti-IL-1β (canakinumab): dramatic hsCRP reduction; CANTOS trial.
• Methotrexate: not effective for cardiovascular prevention (CIRT trial).
• Niacin: minimal effect.
• Fibrates: modest reduction.

When to Test hsCRP

• Adults with intermediate cardiovascular risk to refine assessment.
• Adults considering statin therapy at intermediate risk.
• Adults with family history of cardiovascular disease.
• Some experts recommend in adults with diabetes for risk assessment.
• Not routinely in adults already on statin therapy.
• Not during acute illness or recent surgery (false elevation).
• If elevated initially, repeat in 2 weeks to confirm chronic vs acute.
• Use two measurements 2 weeks apart for accuracy.

Interpreting hsCRP in Diabetes

• Adults with diabetes typically have hsCRP 2-5 mg/L.
• This is higher than non-diabetic peers but reflects baseline diabetes inflammation.
• Reduction with interventions is the meaningful change.
• Track over time rather than single value.
• Consider in context of other risk factors.
• ADA doesn’t routinely recommend hsCRP testing but acknowledges value in selected adults.
• ACC/AHA risk calculator can use hsCRP as risk enhancer.

The Bottom Line

hsCRP (high-sensitivity C-reactive protein) measures systemic inflammation in the body. Produced by liver in response to inflammation; “high-sensitivity” testing detects low levels associated with chronic disease. hsCRP is independently associated with cardiovascular disease risk — elevated values predict heart attacks and strokes even when cholesterol levels are normal. Categories: under 1 mg/L low risk, 1-3 average, over 3 high, over 10 acute inflammation. Diabetes typically elevates hsCRP due to chronic low-grade inflammation — baseline 2-5 mg/L is common, higher than non-diabetic peers. Mechanisms include hyperglycemia stimulating inflammatory cytokines, adipose tissue (especially visceral fat) producing TNF-α and IL-6, insulin resistance, and often coexisting hypertension and obesity. The JUPITER trial demonstrated that statin therapy in adults with normal LDL but elevated hsCRP reduced cardiovascular events by 44% — establishing hsCRP as independent risk marker. ACC/AHA risk calculator includes hsCRP as risk enhancer; useful for adults at intermediate cardiovascular risk to refine decision on statin therapy. Effective hsCRP reduction interventions: Mediterranean diet (15-40% reduction), weight loss (5-10% body weight reduces hsCRP 25-50%), regular exercise (150 min/week, both aerobic and resistance), glucose control, smoking cessation (major reduction), sleep adequacy (7-9 hours), stress management, address periodontal disease, treat sleep apnea, omega-3 from fatty fish 2x weekly, limit alcohol, avoid processed foods/refined carbs/trans fats. Medications that reduce hsCRP: statins (direct anti-inflammatory beyond cholesterol lowering), aspirin (modest), SGLT2 inhibitors and GLP-1 agonists (modest), metformin (modest). Not routinely recommended for all adults; most useful for intermediate cardiovascular risk to refine statin decision. For adults with type 2 diabetes, baseline elevation is expected; reduction with comprehensive lifestyle changes correlates with reduced cardiovascular risk. See our broader diabetes heart attack risk guide for context.

eGFR (estimated glomerular filtration rate) measures how well kidneys filter blood per minute. Calculated from serum creatinine using equations that account for age and sex; the 2021 CKD-EPI equation replaced the previous version that included a race adjustment. Normal eGFR is ≥90 mL/min/1.73 m²; CKD is diagnosed at less than 60 for 3+ months. eGFR is the most commonly used measure of kidney function in clinical practice. CKD staging: Stage 1 (eGFR ≥90 with kidney damage), Stage 2 (60-89), Stage 3a (45-59), Stage 3b (30-44), Stage 4 (15-29), Stage 5 (less than 15, dialysis or transplant). Diabetes is the leading cause of kidney disease in the U.S. — about 40% of adults on dialysis have diabetes. Diabetic nephropathy typically progresses: microalbuminuria → macroalbuminuria → declining eGFR → kidney failure. Annual eGFR monitoring detects early decline; aggressive intervention can slow or stabilize progression. Many diabetes medications require dose adjustment based on eGFR: metformin (full dose if eGFR ≥45, reduced 30-45, contraindicated under 30), SGLT2 inhibitors (eGFR ≥20-25 acceptable), sulfonylureas (glipizide preferred), DPP-4 inhibitors (most need adjustment; linagliptin doesn’t), GLP-1 agonists (generally safe), insulin (may need less in CKD due to slower clearance).

CKD Staging by eGFR

Diabetes Medication Dosing by eGFR

Why Diabetes Causes Kidney Disease

• Chronic hyperglycemia damages glomerular capillary walls.
• Hyperfiltration in early diabetes overworks kidneys.
• Hypertension (common with diabetes) damages blood vessels.
• Inflammation accelerates damage.
• Advanced glycation end products (AGEs) deposit in kidneys.
• Renin-angiotensin-aldosterone system activation.
• Genetic susceptibility varies among adults.
• Risk factors: longer diabetes duration, poor glucose control, hypertension, smoking, family history.

Slowing Progression

• Glucose control: A1C under 7% (individualize based on comorbidities).
• Blood pressure control: under 130/80 mmHg.
• ACE inhibitor or ARB: first-line if microalbuminuria or hypertension.
• SGLT2 inhibitor: kidney protection demonstrated in CREDENCE, DAPA-CKD, EMPA-KIDNEY.
• Finerenone (Kerendia): nonsteroidal MR antagonist for T2D + CKD.
• GLP-1 agonist: modest kidney benefit.
• Weight loss: 5-10% improves multiple risk factors.
• Smoking cessation: significantly reduces progression.
• Sodium reduction: under 2.3 g daily.
• Protein moderation: 0.8 g/kg body weight if not malnourished.
• Avoid NSAIDs: ibuprofen, naproxen damage kidneys.
• Avoid contrast media when possible: discuss with provider before scans.

2021 Race-Free eGFR Equation

• Prior CKD-EPI equation included race-based adjustment (Black race coefficient).
• 2021 CKD-EPI equation removes race adjustment.
• Changes were made because race is a social construct, not biological.
• Race-free equation slightly increases eGFR estimates for Black adults compared with prior equation.
• May affect medication dose adjustments and CKD staging classifications.
• Cystatin C-based eGFR equation is more accurate but less widely available.
• Most labs in U.S. have adopted 2021 equation.
• Discuss with provider if recent change in calculated eGFR appears.

When to See a Nephrologist

• eGFR consistently under 45.
• Rapid eGFR decline (over 5 mL/min/year).
• Persistent macroalbuminuria (ACR over 300).
• Difficult-to-control hypertension.
• Resistant hyperkalemia.
• Suspected non-diabetic kidney disease.
• Preparation for dialysis (eGFR under 30).
• Kidney transplant evaluation.
• Difficult cases for primary care to manage alone.

The Bottom Line

eGFR measures kidney function — how well kidneys filter blood per minute. Calculated from serum creatinine using equations accounting for age and sex; the 2021 CKD-EPI equation replaced the prior race-based version. Normal eGFR is ≥90; CKD is diagnosed at less than 60 for 3+ months. CKD staging: Stage 1 (eGFR ≥90 with kidney damage), Stage 2 (60-89), Stage 3a (45-59), Stage 3b (30-44), Stage 4 (15-29), Stage 5 (under 15, dialysis or transplant). Diabetes is the leading cause of kidney disease in the U.S. — about 40% of adults on dialysis have diabetes. Diabetic nephropathy typically progresses: microalbuminuria → macroalbuminuria → declining eGFR → kidney failure. Annual eGFR monitoring detects early decline; aggressive intervention can slow or stabilize progression. Critical medication dosing implications: metformin (full dose if eGFR ≥45, reduced 30-45, contraindicated under 30), SGLT2 inhibitors (most can continue down to eGFR 20-25), sulfonylureas (glipizide preferred over glyburide in CKD), DPP-4 inhibitors (most need adjustment; linagliptin doesn’t), GLP-1 agonists (generally safe), insulin (may need less in CKD due to slower clearance — monitor for hypoglycemia). Slowing progression: glucose control (A1C under 7%), blood pressure control (under 130/80), ACE inhibitor or ARB (first-line), SGLT2 inhibitor (kidney protection from CREDENCE, DAPA-CKD, EMPA-KIDNEY trials), finerenone (Kerendia) for T2D + CKD, GLP-1 agonist (modest benefit), weight loss, smoking cessation, sodium reduction, modest protein moderation, avoid NSAIDs (ibuprofen, naproxen damage kidneys), avoid unnecessary contrast media. Nephrology referral for eGFR under 45, rapid decline (over 5/year), persistent macroalbuminuria, difficult hypertension, or preparing for dialysis. For adults with type 2 diabetes, annual eGFR monitoring is essential alongside microalbumin testing; early detection enables interventions that preserve kidney function and prevent dialysis. See our broader nephropathy guide for context.

The microalbumin test detects small amounts of albumin (protein) in urine — the earliest sign of diabetic kidney disease. Damaged kidneys allow albumin to leak into urine; the leak is detectable years before kidney function declines on standard tests like creatinine or eGFR. Early detection enables intervention that may slow or reverse progression. ADA recommends annual microalbumin testing for adults with type 2 diabetes from diagnosis; type 1 diabetes starting 5 years after diagnosis. Albumin-to-creatinine ratio (ACR) is the standard measure: under 30 mg/g normal, 30-300 microalbuminuria, over 300 macroalbuminuria. Results may vary day-to-day, so abnormal results should be confirmed with repeat testing 1-2 times over 3-6 months. Elevated microalbumin indicates early diabetic nephropathy and increased cardiovascular risk; standard action steps include ACE inhibitor or ARB therapy (reduces ACR 30-50%), SGLT2 inhibitor for kidney protection (CREDENCE, DAPA-CKD trials), aggressive blood pressure control (target under 130/80), tight glucose control, finerenone (Kerendia) for adults with T2D and CKD, weight loss if overweight, sodium reduction, modest protein moderation, and smoking cessation. Often reversible if caught early.

Albumin-to-Creatinine Ratio Categories

Why Microalbumin Matters

• Earliest detectable sign of diabetic kidney damage.
• Years before creatinine or eGFR shows decline.
• Strong predictor of cardiovascular events independent of kidney function.
• Identifies adults who benefit most from ACE inhibitor/ARB therapy.
• Identifies adults who benefit most from SGLT2 inhibitors.
• Often reversible with early intervention — can return to normal.
• If untreated, progresses to macroalbuminuria, then to kidney failure.
• End-stage kidney disease (dialysis) is preventable through early screening and action.

How the Test Is Performed

• Random spot urine sample (most common).
• First morning urine often preferred (more concentrated).
• Lab measures albumin and creatinine concentrations.
• Calculates ACR (albumin/creatinine).
• Results typically available within 24-48 hours.
• 24-hour urine collection: alternative; less commonly used.
• Some labs offer “albumin only” but ACR is preferred.
• Point-of-care tests available at some clinics.

Factors That May Cause False-Positive Results

• Recent strenuous exercise (within 24 hours).
• Fever, acute illness.
• Urinary tract infection.
• Menstruation (avoid testing during).
• Heart failure decompensation.
• Severe hypertension (uncontrolled).
• Pregnancy (preeclampsia screening uses separate criteria).
• Recent high-protein meal.
• Repeat testing in 1-3 months to confirm persistent elevation.

Treatment for Microalbuminuria

• ACE inhibitors: lisinopril, ramipril, enalapril, benazepril — first-line.
• ARBs: losartan, valsartan, irbesartan, telmisartan — alternative for ACE intolerance.
• SGLT2 inhibitors: empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana) — kidney protection.
• Finerenone (Kerendia): nonsteroidal mineralocorticoid receptor antagonist; for T2D + CKD.
• GLP-1 agonists: semaglutide (Ozempic), dulaglutide (Trulicity) — modest kidney benefit.
• Tight glucose control: A1C under 7%; modify based on comorbidities.
• Aggressive blood pressure: target under 130/80.
• Reduce sodium: under 2.3 g daily.
• Modest protein reduction: 0.8 g/kg body weight if not malnourished.
• Weight loss: 5-10% body weight if overweight.
• Smoking cessation: significantly reduces progression.

SGLT2 Inhibitors for Kidney Protection

• CREDENCE trial: canagliflozin reduced kidney failure by 32% in T2D + CKD.
• DAPA-CKD trial: dapagliflozin reduced kidney decline (including in non-diabetic CKD).
• EMPA-KIDNEY trial: empagliflozin reduced kidney progression.
• Recommended for adults with diabetes + microalbuminuria/CKD.
• Used in addition to (not instead of) ACE/ARB.
• Side effects: genital yeast infections, dehydration, rare diabetic ketoacidosis.
• Discontinue temporarily during acute illness or surgery.
• Monitor kidney function periodically.

Frequency Recommendations

• Adults with type 2 diabetes: annually from diagnosis.
• Adults with type 1 diabetes: annually starting 5 years after diagnosis.
• Pregnant women with diabetes: each trimester.
• Adults with microalbuminuria: every 6 months to monitor.
• Adults with macroalbuminuria: every 3-6 months.
• Adults on dialysis: ACR not routinely useful.
• Adults with recent abnormal result: repeat in 1-3 months to confirm persistence.
• Children with type 1 diabetes: start at age 11 or after 5 years of diabetes.

The Bottom Line

The microalbumin test detects small amounts of albumin in urine — the earliest sign of diabetic kidney disease. Damaged kidneys allow albumin to leak into urine; the leak is detectable years before kidney function declines on standard tests. Early detection enables intervention that may slow or reverse progression. ADA recommends annual microalbumin testing for adults with type 2 diabetes from diagnosis; type 1 diabetes starting 5 years after diagnosis. Albumin-to-creatinine ratio (ACR) is the standard measure: under 30 mg/g normal, 30-300 microalbuminuria (early diabetic nephropathy), over 300 macroalbuminuria (overt nephropathy). Abnormal results should be confirmed with repeat testing 1-2 times over 3-6 months. Factors causing false-positive: recent strenuous exercise, fever/illness, UTI, menstruation, severe hypertension. Elevated microalbumin indicates early diabetic nephropathy and increased cardiovascular risk. Treatment: ACE inhibitors (lisinopril, ramipril) or ARBs (losartan, valsartan) reduce ACR 30-50%; SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) for kidney protection (CREDENCE, DAPA-CKD, EMPA-KIDNEY trials); finerenone (Kerendia) for T2D + CKD; GLP-1 agonists (semaglutide, dulaglutide) for modest kidney benefit; aggressive glucose control (A1C under 7%); aggressive blood pressure (under 130/80); sodium reduction under 2.3 g daily; modest protein moderation (0.8 g/kg if not malnourished); weight loss 5-10% if overweight; smoking cessation. Often reversible if caught early — combined approach may return ACR to normal. End-stage kidney disease requiring dialysis is preventable through annual screening and early action. For adults with type 2 diabetes, microalbumin testing is among the most important annual screenings; insist on it as part of routine diabetes care. See our broader nephropathy symptoms guide for context.

The lipid panel measures fats circulating in blood — total cholesterol, LDL cholesterol (“bad cholesterol”; main target for CVD risk reduction), HDL cholesterol (“good cholesterol”; higher better), and triglycerides. Non-HDL cholesterol (total minus HDL) is an alternative target. ADA recommends annual lipid panel for adults with diabetes; more often if abnormal. Adults with type 2 diabetes have 2-4 fold higher cardiovascular disease risk than non-diabetic peers due to diabetic dyslipidemia (high triglycerides, low HDL, increased small dense LDL), insulin resistance effects on lipid metabolism, chronic hyperglycemia damaging blood vessels, and often coexisting hypertension and obesity. ADA lipid targets: LDL under 100 mg/dL standard, under 70 with established CVD, under 55 with very high risk; non-HDL under 130 standard, under 100 with CVD; HDL over 40 (men) or 50 (women); triglycerides under 150. Statin therapy is recommended for most adults with diabetes age 40-75 — moderate intensity at minimum; high intensity for established CVD. Add ezetimibe if LDL not at target; PCSK9 inhibitors (Repatha, Praluent) for adults not achieving target on statins; bempedoic acid for statin intolerance; icosapent ethyl (Vascepa) for adults with triglycerides 150-499 on statin therapy (REDUCE-IT trial). Improve glucose control to improve triglycerides and HDL; weight loss, exercise, diet improve all lipid measures.

Normal vs Target Values

Diabetic Dyslipidemia Pattern

• Elevated triglycerides (often 150-400 mg/dL).
• Low HDL cholesterol.
• LDL particles tend to be smaller and denser (more atherogenic).
• Apolipoprotein B (ApoB) elevated.
• LDL particle number (LDL-P) elevated.
• Total cholesterol may be normal — masking the atherogenic pattern.
• Improves with: glucose control, weight loss, exercise, low-carb or Mediterranean diet.
• SGLT2 inhibitors modestly improve lipids.
• GLP-1 agonists modestly improve lipids.

Statin Therapy

• ADA: most adults with diabetes age 40-75 should be on statin.
• Moderate intensity: atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg.
• High intensity: atorvastatin 40-80 mg, rosuvastatin 20-40 mg.
• Indication for high intensity: established CVD, multiple risk factors.
• LDL reduction: 30-50% (moderate) or 50%+ (high intensity).
• Monitor for muscle aches (myalgia) and liver enzymes.
• Coenzyme Q10 supplementation for statin myalgia — modest evidence.
• Switch statins if intolerance — many adults tolerate different statin.
• Pregnancy: contraindicated; switch before conception.

Beyond Statins

• Ezetimibe (Zetia): blocks cholesterol absorption; add to statin if LDL not at target.
• PCSK9 inhibitors (Repatha, Praluent): injectable; very effective LDL reduction; for those not at target on statin + ezetimibe.
• Bempedoic acid (Nexletol): oral; alternative for statin intolerance.
• Icosapent ethyl (Vascepa): prescription EPA; for triglycerides 150-499 on statin (REDUCE-IT trial).
• Fenofibrate: for severe hypertriglyceridemia (over 500); pancreatitis prevention.
• Niacin: rarely used now; modest HDL improvement but cardiovascular trials negative.
• Bile acid sequestrants: occasional use; cholestyramine, colesevelam.
• Inclisiran (Leqvio): twice-yearly injection; PCSK9 inhibitor.

Lifestyle Improvement

• Mediterranean diet — best evidence for lipid improvement.
• Reduce saturated fat to under 10% of calories.
• Eliminate trans fats.
• Increase omega-3 fatty acids (fish 2x weekly).
• Soluble fiber (oats, beans, fruits) lowers LDL.
• Plant sterols/stanols supplements modestly lower LDL.
• Aerobic exercise 150+ min/week — raises HDL, lowers triglycerides.
• Weight loss — improves all lipid measures.
• Alcohol moderation — excess raises triglycerides.
• Smoking cessation — improves HDL.
• Limit refined carbohydrates — lowers triglycerides.

Triglycerides and Diabetes

• Often elevated in adults with diabetes.
• Strongly affected by carbohydrate intake.
• Improvements with glucose control.
• Severe hypertriglyceridemia (over 500): pancreatitis risk.
• Fenofibrate for severe elevation.
• Icosapent ethyl (Vascepa) for moderate elevation on statin.
• Low-carb diets significantly improve triglycerides.
• Weight loss improves triglycerides.
• Limit alcohol — major triglyceride raiser.
• Aerobic exercise lowers triglycerides.

How to Prepare

• Fast 9-12 hours before test (water allowed).
• Schedule for morning to minimize fasting impact.
• Continue regular medications.
• Note recent illnesses (acute illness can affect results).
• Avoid heavy alcohol use day before.
• Bring list of medications including supplements.
• Bring previous lipid results for comparison.
• Some labs offer non-fasting lipid panel — discuss with provider.

The Bottom Line

The lipid panel measures fats circulating in blood — total cholesterol, LDL (“bad cholesterol”; main target for CVD risk reduction), HDL (“good cholesterol”; higher better), and triglycerides. ADA recommends annual lipid panel for adults with diabetes. Adults with type 2 diabetes have 2-4 fold higher cardiovascular disease risk due to diabetic dyslipidemia (high triglycerides, low HDL, increased small dense LDL particles), insulin resistance, chronic hyperglycemia, and often coexisting hypertension and obesity. ADA lipid targets tiered by risk: LDL under 100 mg/dL standard, under 70 with established CVD, under 55 with very high risk; non-HDL under 130 standard, under 100 with CVD; HDL over 40 (men) or 50 (women); triglycerides under 150. Statin therapy is recommended for most adults with diabetes age 40-75 — moderate intensity (atorvastatin 10-20, rosuvastatin 5-10) at minimum; high intensity (atorvastatin 40-80, rosuvastatin 20-40) for established CVD; LDL reduction 30-50% or 50%+. Beyond statins: ezetimibe (add if not at target), PCSK9 inhibitors (Repatha, Praluent — injectable, very effective), bempedoic acid (for statin intolerance), icosapent ethyl/Vascepa (for triglycerides 150-499 on statin; REDUCE-IT trial), fenofibrate (severe hypertriglyceridemia). Lifestyle improvement: Mediterranean diet (best evidence), reduce saturated fat under 10%, eliminate trans fats, omega-3 fish 2x weekly, soluble fiber, aerobic exercise 150+ min weekly raises HDL and lowers triglycerides, weight loss improves all measures, alcohol moderation, smoking cessation, limit refined carbohydrates lowers triglycerides. Improve glucose control to improve triglycerides and HDL. SGLT2 inhibitors and GLP-1 agonists modestly improve lipids. Triglycerides over 500 carry pancreatitis risk and warrant specific treatment. For adults with type 2 diabetes, annual lipid monitoring and aggressive lipid management is critical for cardiovascular disease prevention — the leading cause of death in diabetes. See our broader diabetes and cholesterol guide for context.

The comprehensive metabolic panel (CMP) is a blood test measuring 14 substances providing information about overall metabolic health, kidney function, liver function, electrolyte balance, and blood sugar. CMP is one of the most commonly ordered blood tests and a standard annual test for adults with diabetes. The measures include glucose, calcium, sodium, potassium, chloride, bicarbonate (CO2), blood urea nitrogen (BUN), creatinine, eGFR (estimated glomerular filtration rate), albumin, total protein, alkaline phosphatase, ALT (alanine aminotransferase), AST (aspartate aminotransferase), and bilirubin. Different from basic metabolic panel (BMP) which has 8 measures (no liver enzymes), CMP is preferred for adults with diabetes because it includes liver function tests — non-alcoholic fatty liver disease (NAFLD) affects 50-70% of adults with type 2 diabetes. Key measures for diabetes monitoring: glucose (fasting 70-99 normal, 100-125 prediabetes, ≥126 diabetes on 2 occasions), eGFR (under 60 indicates CKD; affects medication dosing especially metformin and SGLT2 inhibitors), creatinine (kidney dysfunction marker), potassium (affected by ACE inhibitors, spironolactone), ALT/AST (elevation suggests fatty liver). ADA recommends CMP at least annually; more frequently with kidney disease, recent medication starts, or elevated liver enzymes.

CMP Components and Normal Ranges

Key Diabetes Measures

• Glucose: fasting; diagnostic for diabetes; monitor with A1C separately.
• eGFR: kidney function; affects medication choices.
• Creatinine: confirms kidney function status.
• BUN/Creatinine ratio: distinguishes dehydration from kidney issues.
• Potassium: medication effects monitored.
• ALT/AST: fatty liver screening — elevated in NAFLD.
• Albumin: nutritional status.

What Elevated ALT/AST Means in Diabetes

• Non-alcoholic fatty liver disease (NAFLD) — 50-70% of adults with T2D have NAFLD.
• NASH (non-alcoholic steatohepatitis) — more advanced; can progress to cirrhosis.
• Metformin can elevate liver enzymes mildly (typically minor).
• Statins can mildly elevate ALT.
• Acetaminophen overuse — significant elevations.
• Alcohol-related liver disease.
• Hepatitis B or C.
• FIB-4 score calculation uses AST + age + ALT to estimate liver fibrosis.
• Persistent elevation warrants further evaluation (FibroScan, hepatologist consultation).

eGFR and CKD Staging

How to Prepare for CMP

• Fast 8-12 hours before test (water allowed).
• Schedule for morning to minimize fasting impact.
• Continue regular medications (unless specifically instructed otherwise).
• Note timing of last metformin dose if relevant.
• Avoid extreme exercise day before test.
• Bring list of medications.
• Bring previous lab results for comparison.
• Discuss results with healthcare provider — don’t interpret alone.
• Don’t smoke immediately before (can affect some measures).
• Tell phlebotomist if you have small or difficult veins.

Frequency Recommendations

• Adults with diabetes: annually at minimum.
• Adults with CKD stage 3 or higher: every 6 months.
• Adults with elevated ALT/AST: every 6 months.
• Adults starting new medications affecting kidneys/liver: within 3 months.
• Adults on metformin with reduced kidney function: every 3-6 months.
• Adults on diuretics, ACE inhibitors, ARBs: every 6-12 months for potassium.
• Adults with electrolyte abnormalities: more frequently.
• Pregnant women with diabetes: trimester monitoring as ordered.

The Bottom Line

The comprehensive metabolic panel (CMP) is a blood test measuring 14 substances providing information about overall metabolic health, kidney function, liver function, electrolyte balance, and blood sugar. CMP is one of the most commonly ordered blood tests and a standard annual test for adults with diabetes. Measures include glucose, calcium, sodium, potassium, chloride, bicarbonate, BUN, creatinine, eGFR, albumin, total protein, alkaline phosphatase, ALT, AST, and bilirubin. CMP is preferred over basic metabolic panel (BMP, 8 measures) for adults with diabetes because it includes liver function tests — NAFLD affects 50-70% of adults with type 2 diabetes. Key measures for diabetes monitoring: glucose (fasting), eGFR (kidney function affects medication dosing especially metformin and SGLT2 inhibitors — discontinue metformin if eGFR under 30), creatinine, BUN, potassium (affected by ACE inhibitors and diuretics), ALT/AST (NAFLD screening). eGFR staging: ≥90 normal, 60-89 mild reduction, 30-59 CKD, under 30 severe CKD or kidney failure. Elevated ALT/AST suggests NAFLD, NASH, alcohol-related liver disease, hepatitis, or medication effects; FIB-4 score (using AST + age + ALT) estimates liver fibrosis; persistent elevation warrants hepatologist evaluation. Preparation: fast 8-12 hours, morning appointment, continue regular medications, list of meds, previous lab results for comparison. ADA recommends CMP at least annually for adults with diabetes; more frequently with kidney disease, elevated liver enzymes, recent medication changes, or on diuretics/ACE inhibitors. For adults with type 2 diabetes, CMP provides essential routine surveillance across multiple organ systems. See our broader diabetes detection guide for context.